Biologic agents in rheumatology: Safety considerations

被引：5
|
作者：
Lee, Susan J. [1 ]
Kavanaugh, Arthur [1 ]
机构：
[1] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, Ctr Innovat Therapy, San Diego, CA 92103 USA
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2006年 / 32卷
关键词：
D O I：
10.1016/S0889-857X(07)70003-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3 / 10
页数：8
相关论文
共 50 条
  • [31] Safety of infliximab and other biologic agents in the inflammatory bowel diseases
    Reddy, Jagadeshwar G.
    Loftus, Edward V., Jr.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2006, 35 (04) : 837 - +
  • [32] Safety of treatment with biologic agents in a general hospital: preliminary data
    Egoavil Rojas, Cecilia Magdalena
    Almenara de Riquer, Susana
    Salazar Garcia, Carlos
    Londono Ramirez, Ana Carolina
    Zapater Hernandez, Pedro
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 40 - 41
  • [33] Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment
    Ozguler, Yesim
    Hatemi, Gulen
    Ugurlu, Serdal
    Seyahi, Emire
    Melikoglu, Melike
    Borekci, Sermin
    Atahan, Ersan
    Ongen, Hurrem Gul
    Hamuryudan, Vedat
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [34] Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
    Horton, Sarah
    Buch, Maya H.
    Emery, Paul
    DRUG HEALTHCARE AND PATIENT SAFETY, 2010, 2 : 101 - 119
  • [35] Biologic targeted therapies in pediatric rheumatology
    Bachelez, Herve
    Berthelot, Jean-Marie
    Bouhnik, Yoram
    Bruckert, Eric
    Claudepierre, Pascal
    Constantin, Arnaud
    de Bandt, Michel
    Fautrel, Bruno
    Gaudin, Philippe
    Goeb, Vincent
    Gossec, Laure
    Gottenberg, Jacques-Eric
    Goupille, Philippe
    Hachulla, Eric
    Huet, Isabelle
    Jullien, Denis
    Launay, Odile
    Lemann, Marc F.
    Lequerre, Thierry
    Maillefert, Jean-Francis
    Mariette, Xavier
    Marolleau, Jean-Pierre
    Martinez, Valerie
    Masson, Charles
    Morel, Jacques
    Mouthon, Luc
    Thao Pham
    Pol, Stanislas
    Puechal, Xavier
    Richette, Pascal
    Saraux, Alain
    Schaeverbeke, Thierry
    Sellam, Jeremie
    Blacher, Jacques
    Soubrier, Martin
    Sudre, Anne
    Viguier, Manuelle
    Vittecoq, Olivier
    Wendling, Daniel
    Sibilia, Jean
    JOINT BONE SPINE, 2014, 81 : 5 - 48
  • [36] 25 years of biologic DMARDs in rheumatology
    Marc Feldmann
    Ravinder N. Maini
    Enrique R. Soriano
    Vibeke Strand
    Tsutomu Takeuchi
    Nature Reviews Rheumatology, 2023, 19 : 761 - 766
  • [37] 25 years of biologic DMARDs in rheumatology
    Feldmann, Marc
    Maini, Ravinder N.
    Soriano, Enrique R.
    Strand, Vibeke
    Takeuchi, Tsutomu
    NATURE REVIEWS RHEUMATOLOGY, 2023, 19 (12) : 761 - 766
  • [38] Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety
    Al-Mayouf, Sulaiman M.
    Alenazi, Abdullatif
    AlJasser, Hind
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (06) : 600 - 605
  • [39] CONSIDERATIONS ON SAFETY OF CERTAIN BIOLOGICAL AGENTS FOR ARTHROPOD CONTROL
    SMITH, RF
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 1973, 48 (06) : 685 - 698
  • [40] Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
    Mishra, Richa
    Singh, Vijay
    Pritchard, Charles H.
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (04) : 481 - 484
12345